OR WAIT null SECS
Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.
Matthieu Egloff, product director with ATMI LifeSciences, discusses the need for larger, special reactors that can provide the necessary conditions for the production of fragile cells on a larger scale.
As the demand for larger amounts of stem cells and other fragile cells grows, biopharmaceutical companies are struggling with how to effectively produce these specialized biological materials in larger quantities. ATMI LifeSciences has developed a new reactor to meet that need. Product Director Matthieu Egloff spoke with the
Pharmaceutical Sciences, Manufacturing & Marketplace Report
about the special conditions required for the larger-scale production of fragile cells and how its new Xpansion reactor was designed to provide them.
A written version of the interview also may be found